9 Spam-Free Article(s) Found
Sort:
Date
Filter:
All
Symbol Name Last Close Mkt Cap DailyStocks'
Rating
Our DailyStocks’ Rating System is a proprietary algorithm that combines the vote of the investor community and legendary trader Richard Dennis’ Turtle Trader System and the System Rules of the Turtle Traders Each day, we generate Buy, Sell, Uptrend or Downtrend signals for 3000 Stocks in the U.S. Markets.
Vote Now!
Thursday’s Close
EYPT EyePoint Pharmaceuticals, Inc. $2.35 $175.1M N/A
Article Searches
Implied Volatility Surging for EyePoint Pharmaceuticals (EYPT) Stock Options http://www.zacks.com/stock/news/339971/implied-volatility-surging-for-eyepoint-pharmaceuticals-eypt-stock-options?cid=CS-ZC-FT-339971 Nov 29, 2018 - Investors need to pay close attention to EyePoint Pharmaceuticals (EYPT) stock based on the movements in the options market lately.
EyePoint Pharmaceuticals, Inc. (EYPT) CEO Nancy Lurker on Q1 2019 Results - Earnings Call Transcript https://seekingalpha.com/article/4219112-eyepoint-pharmaceuticals-inc-eypt-ceo-nancy-lurker-q1-2019-results-earnings-call-transcript?source=feed_sector_healthcare Nov 06, 2018 - EyePoint Pharmaceuticals, Inc. (NASDAQ:EYPT) Q1 2019 Results Conference Call November 06, 2018 08:00 AM ET Executives Nancy Lurker - President and Chief Executive Officer David Price - Chief Financial
EyePoint (EYPT) Gets FDA Approval for Eye Therapy Yutiq http://www.zacks.com/stock/news/328751/eyepoint-eypt-gets-fda-approval-for-eye-therapy-yutiq?cid=CS-ZC-FT-328751 Oct 17, 2018 - EyePoint (EYPT) gains an FDA approval for its eye therapy Yutiq to help cure chronic non-infectious uveitis affecting the posterior segment of the eye.
Implied Volatility Surging for EyePoint Pharmaceuticals (EYPT) Stock Options http://www.zacks.com/stock/news/325649/implied-volatility-surging-for-eyepoint-pharmaceuticals-eypt-stock-options?cid=CS-ZC--325649 Oct 01, 2018 - Investors need to pay close attention to EyePoint Pharmaceuticals (EYPT) stock based on the movements in the options market lately.
EyePoint Pharmaceuticals, Inc. (EYPT) CEO Nancy Lurker on Q4 2018 Results - Earnings Call Transcript https://seekingalpha.com/article/4205783-eyepoint-pharmaceuticals-inc-eypt-ceo-nancy-lurker-q4-2018-results-earnings-call-transcript?source=feed_sector_transcripts Sep 12, 2018 - EyePoint Pharmaceuticals, Inc. (NASDAQ:EYPT) Q4 2018 Earnings Conference Call September 12, 2018 08:30 AM ET Executives David Price - CFO Nancy Lurker - President and CEO Leonard Ross - VP, Finance an
EyePoint Pharmaceuticals (EYPT) Reports Q4 Loss, Tops Revenue Estimates http://www.zacks.com/stock/news/322618/eyepoint-pharmaceuticals-eypt-reports-q4-loss-tops-revenue-estimates?cid=CS-ZC--322618 Sep 12, 2018 - EyePoint Pharmaceuticals (EYPT) delivered earnings and revenue surprises of -111.11% and 6.72%, respectively, for the quarter ended June 2018. Do the numbers hold clues to what lies ahead for the stock?
"Right To Try" Brings Good News for Biotech Sector: 5 Picks http://www.zacks.com/stock/news/305964/right-to-try-brings-good-news-for-biotech-sector-5-picks?cid=CS-ZC-FT-305964 Jun 01, 2018 - Passage of the Right To Try law and WHO's focus on assessing the quality of bio-similar drugs is expected to benefit biotech stocks.
EyePoint Pharmaceuticals' (EYPT) CEO Nancy Lurker on Q3 2018 Results - Earnings Call Transcript https://seekingalpha.com/article/4171526-eyepoint-pharmaceuticals-eypt-ceo-nancy-lurker-q3-2018-results-earnings-call-transcript?source=feed_sector_healthcare May 08, 2018 - EyePoint Pharmaceuticals, Inc. (NASDAQ:EYPT) Q3 2018 Earnings Conference Call May 8, 2018 4:30 PM ET Executives ‎Barbara Ryan - Head of Investor Relations Nancy Lurker - President and Chief Executive
Will EyePoint Pharmaceuticals (EYPT) Continue to Surge Higher? http://www.zacks.com/stock/news/300049/will-eyepoint-pharmaceuticals-eypt-continue-to-surge-higher?cid=CS-ZC--300049 Apr 20, 2018 - As of late, it has definitely been a great time to be an investor in EyePoint Pharmaceuticals, Inc. (EYPT)

Pages: 1

Page 1